1. Madsen KB, Ersbøll AK, Olsen J, Parner E, Obel C. Geographic analysis of the variation in the incidence of ADHD in a country with free access to healthcare: a Danish cohort study. Int J Health Geogr 2015; 14: 24.

https://doi.org/10.1186/s12942-015-0018-4

PMid:26297014 PMCid:PMC4546292

2. Sayal K, Prasad V, Daley D, Ford T, Coghill D. ADHD in children and young people: prevalence, care pathways, and service provision. Lancet Psychiatry 2018; 5: 175-86.

https://doi.org/10.1016/S2215-0366(17)30167-0

3. Simon V, Czobor P, Bálint S, Mészáros Á, Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: Meta-analysis. Br J Psychiatry 2009; 194: 204-11.

https://doi.org/10.1192/bjp.bp.107.048827

PMid:19252145

4. Willcutt EG. The Prevalence of DSM-IV Attention-Deficit/Hyperactivity Disorder: A Meta-Analytic Review. Neurotherapeut 2012; 9: 490-9.

https://doi.org/10.1007/s13311-012-0135-8

PMid:22976615 PMCid:PMC3441936

5. Williamson D, Johnston C. Gender differences in adults with attention-deficit/hyperactivity disorder: A narrative review. Clin Psychol Rev 2015; 40: 15-27.

https://doi.org/10.1016/j.cpr.2015.05.005

PMid:26046624

6. American Psychiatric Association, D.-5 T. F. Diagnostic and statistical manual of mental disorders: DSM-5TM. Am Psychiatr Publ 2013.

https://doi.org/10.1176/appi.books.9780890425596

7. Volkow ND, Swanson JM. Adult attention deficit-hyperactivity disorder. N Engl J Med 2013; 369: 1935-44.

https://doi.org/10.1056/NEJMcp1212625

PMid:24224626 PMCid:PMC4827421

8. Solberg BS, Zayats T, Posserud MB, Halmøy A, Engeland A, Haavik J, et al. Patterns of Psychiatric Comorbidity and Genetic Correlations Provide New Insights Into Differences Between Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorder. Biol Psychiatry 2019; 86: 587-98.

https://doi.org/10.1016/j.biopsych.2019.04.021

PMid:31182215

9. Daley D, Jacobsen R, Lange A, Sørensen A, Walldorf J. Private and Social Costs of ADHD: COST ANALYSIS. University Press of Southern Denmark, 2014.

https://doi.org/10.1093/acprof:oso/9780198745556.003.0001

PMid:24910021

10. Sobanski E. Psychiatric comorbidity in adults with attention-deficit/hyperactivity disorder (ADHD). Eur Arch Psychiatry Clin Neurosci 2006; 256 Suppl 1: i26-31.

https://doi.org/10.1007/s00406-006-1004-4

PMid:16977548

11. Young S, Emilsson B, Sigurdsson JF, Khondoker M, Philipp-Wiegmann F, Baldursson G, et al. A randomized controlled trial reporting functional outcomes of cognitive-behavioural therapy in medication-treated adults with ADHD and comorbid psychopathology. Eur Arch Psychiatr Clin Neurosci 2017; 267: 267-76.

https://doi.org/10.1007/s00406-016-0735-0

PMid:27752827 PMCid:PMC5357275

12. Young S, Khondoker M, Emilsson B, Sigurdsson JF, Philipp-Wiegmann F, Baldursson G, et al. Cognitive-behavioural therapy in medication-treated adults with attention-deficit/hyperactivity disorder and co-morbid psychopathology: a randomized controlled trial using multi-level analysis. Psychol Med 2015; 45: 2793-804.

https://doi.org/10.1017/S0033291715000756

PMid:26022103 PMCid:PMC4595859

13. Biederman J, Wilens T, Mick E, Milberger S, Spencer TJ, Faraone SV. Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatr 1995; 152: 1652-8.

https://doi.org/10.1176/ajp.152.11.1652

PMid:7485630

14. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59: Suppl 20, 22-33; quiz 34-57.

15. Magnússon P, Smári J, Sigurdardóttir D, Baldursson G, Sigmundsson J, Kristjánsson K, et al. Validity of self-report and informant rating scales of adult ADHD symptoms in comparison with a semistructured diagnostic interview. J Atten Disord 2006; 9: 494-503.

https://doi.org/10.1177/1087054705283650

PMid:16481666

16. Kjartansdóttir SH. ADHD teymi. landspitali.is/sjuklingar-adstandendur/teymi-/adhd-teymi/ - apríl 2018.

17. Embætti landlæknis. Vinnulag við greiningu og meðferð athyglisbrests með ofvirkni: Stytt útgáfa leiðbeininga. 2014.

18. National Institute for Health and Care Excellence (NICE). Attention deficit hyperactivity disorder: diagnosis and management (NICE guideline NG87). 2018.

19. Geirs DP, Pottegård A, Halldórsson M, Zoëga H. A nationwide study of attention-deficit/hyperactivity disorder drug use among adults in Iceland 2003-2012. Basic Clin Pharmacol Toxicol 2014; 115: 417-22.

https://doi.org/10.1111/bcpt.12243

PMid:24690162

20. Guðmundsson LS, Einarsson ÓB. Enn aukning í ávísunum ADHD lyfja á Íslandi. Embætti landlæknis (2016). landlaeknir.is/um-embaettid/frettir/frett/item30130/enn-aukning-i-avisunum-adhd-lyfja-a-islandi - maí 2018.

21. Guðlaugsson R. Upplýsingar frá Lyfjastofnun. (2020).

22. Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 2018; 5: 727-38.

https://doi.org/10.1016/S2215-0366(18)30224-4

https://doi.org/10.1016/S2215-0366(18)30269-4

23. Wilens TE, Morrison NR, Prince J. An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults. Expert Rev Neurother 2011; 11: 1443-65.

https://doi.org/10.1586/ern.11.137

PMid:21955201 PMCid:PMC3229037

24. Elíasdóttir GB. Tölur frá Sjúkratryggingum Íslands. SÍ, Reykjavík 2018.

25. Jóhannsson M, Einarsson ÓB, Guðmundsson LS, Bárðarson L. ADHD og misnotkun lyfja I. Embætti landlæknis 2. pistill. Læknablaðið 2013; 99: 537.

26. Karlstad Ø, Zoëga H, Furu K, Bahmanyar S, Martikainen JE, Kieler H, et al. Use of drugs for ADHD among adults-a multinational study among 15.8 million adults in the Nordic countries. Eur J Clin Pharmacol 2016; 72: 1507-14.

https://doi.org/10.1007/s00228-016-2125-y

PMid:27586399 PMCid:PMC5110707

27. Bjarnadottir GD, Haraldsson HM, Rafnar BO, Sigurdsson E, Steingrimsson S, Johannsson M, et al. Prevalent intravenous abuse of methylphenidate among treatment-seeking patients with substance abuse disorders: A descriptive population-based study. J Addict Med 2015; 9: 188-94.

https://doi.org/10.1097/ADM.0000000000000115

PMid:25748561 PMCid:PMC4450903

28. Blöndahl M. Normalkúrfa, z-gildi, t-gildi og hundraðsröð. gba.is/cpadf/kefni/mbs/index.html - maí 2018.

29. Lovibond PF, Lovibond SH. The structure of negative emotional states: comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. Behav Res Ther 1995; 33: 335-43.

https://doi.org/10.1016/0005-7967(94)00075-U

30. Antony MM, Bieling PJ, Cox BJ, Enns MW, Swinson RP. Psychometric properties of the 42-item and 21-item versions of the Depression Anxiety Stress Scales in clinical groups and a community sample. Psychol Assess 1998; 10: 176-81.

https://doi.org/10.1037/1040-3590.10.2.176

31. Ingimarsson B. Próffræðilegt mat á DASS sjálfsmatskvarðanum Þunglyndi, kvíði og streita. Háskóli Íslands, Reykjavík 2010.

32. Liedberg GM, Burckhardt CS, Henriksson C.M. Validity and reliability testing of the Quality of Life Scale, Swedish version in women with fibromyalgia - statistical analyses. Scand J Caring Sci 2005; 19: 64-70.

https://doi.org/10.1111/j.1471-6712.2004.00311.x

PMid:15737168

33. Hrafnsson ÓV, Guðmundsson M. Próffræðilegir eiginleikar Lífsgæðakvarðans (QOLS) / - ICE. Háskóli Íslands, Reykjavík 2007.

34. Wahl AK, Rustøen T, Hanestad BR, Lerdal A, Moum T. Quality of Life in the General Norwegian Population, Measured by the Quality of Life Scale (QOLS-N). Qual Life Res 2004; 13: 1001-9.

https://doi.org/10.1023/B:QURE.0000025583.28948.5b

PMid:15233513

35. Cohen J. Statistical power analysis for the behavioral sciences. Academic Press, 1977.

36. Retz W, Rösler M, Ose C, Scherag A, Alm B, Philipsen A, et al. Multiscale assessment of treatment efficacy in adults with ADHD: A randomized placebo-controlled, multi-centre study with extended-release methylphenidate. World J Biol Psychiatr 2012; 13: 48.

https://doi.org/10.3109/15622975.2010.540257

PMid:21155632 PMCid:PMC3279134

37. Mészáros Á, Czobor P, Bálint S, Komlósi S, Simon V, Bitter I. Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis. Int J Neuropsychopharmacol 2009; 12: 1137-47.

https://doi.org/10.1017/S1461145709990198

PMid:19580697

38. Castells X, Ramos-Quiroga JA, Rigau D, Bosch R, Nogueira M, Vidal X, et al. Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: A meta-regression analysis. CNS Drugs 2011; 25: 157-69.

https://doi.org/10.2165/11539440-000000000-00000

PMid:21254791

39. Castells X, Cunill R, Capellà D. Treatment discontinuation with methylphenidate in adults with attention deficit hyperactivity disorder: A meta-analysis of randomized clinical trials. Eur J Clin Pharmacol 2013; 69: 347-56.

https://doi.org/10.1007/s00228-012-1390-7

PMid:22983311

40. Soendergaard HM, Thomsen PH, Pedersen P, Pedersen E, Poulsen AE, Nielsen JM, et al. Treatment dropout and missed appointments among adults with attention-deficit/hyperactivity disorder: Associations with patient- and disorder-related factors. J Clin Psychiatry 2016; 77: 232-9.

https://doi.org/10.4088/JCP.14m09270

PMid:26761266